Clarius Group LLC Invests $211,000 in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Clarius Group LLC acquired a new position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,938 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of CymaBay Therapeutics during the third quarter valued at $103,475,000. BlackRock Inc. grew its position in shares of CymaBay Therapeutics by 183.2% during the 2nd quarter. BlackRock Inc. now owns 7,504,670 shares of the biopharmaceutical company’s stock worth $82,176,000 after buying an additional 4,854,593 shares during the period. Franklin Resources Inc. grew its position in shares of CymaBay Therapeutics by 13,862.3% during the 1st quarter. Franklin Resources Inc. now owns 3,224,862 shares of the biopharmaceutical company’s stock worth $28,121,000 after buying an additional 3,201,765 shares during the period. Perceptive Advisors LLC grew its position in shares of CymaBay Therapeutics by 450.5% in the 1st quarter. Perceptive Advisors LLC now owns 3,903,255 shares of the biopharmaceutical company’s stock valued at $34,036,000 after purchasing an additional 3,194,262 shares during the period. Finally, Fred Alger Management LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at approximately $32,389,000. 95.03% of the stock is owned by institutional investors.

CymaBay Therapeutics Stock Performance

Shares of CymaBay Therapeutics stock opened at $32.48 on Tuesday. CymaBay Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $32.50. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -33.48 and a beta of 0.32. The company has a fifty day moving average of $31.75 and a 200-day moving average of $23.80.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million. On average, equities research analysts forecast that CymaBay Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at CymaBay Therapeutics

In related news, Director Janet Dorling sold 6,000 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total transaction of $191,820.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Janet Dorling sold 6,000 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total transaction of $191,820.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Charles Mcwherter sold 18,403 shares of the company’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $23.67, for a total transaction of $435,599.01. Following the sale, the insider now owns 15,000 shares of the company’s stock, valued at $355,050. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on CBAY shares. UBS Group restated a “neutral” rating and issued a $32.50 target price (up previously from $25.00) on shares of CymaBay Therapeutics in a research note on Wednesday, February 14th. BTIG Research reissued a “neutral” rating on shares of CymaBay Therapeutics in a report on Tuesday, February 13th. B. Riley reaffirmed a “neutral” rating and issued a $32.50 price objective (up from $29.00) on shares of CymaBay Therapeutics in a report on Tuesday, February 13th. William Blair lowered CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, February 12th. Finally, Lifesci Capital downgraded CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.65.

CymaBay Therapeutics Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).